rais tp worth wait
etrasimod opportun emerg oral agent choic
treatment moderate-to-sever ibd sever effect biolog
approach exist manag ibd receiv feedback safe
effect oral agent like play major lt role manag patient
refractori soc tnf-alpha antagonist project multipl oral agent
enter market longer term think whole captur
refractori popul best-of-bre oral attain
oral agent market share etrasimod may oral agent
market see clinic profil support best agent
ibd market opportun continu expand view ww market
biologics/novel agent growth like continu
option becom avail tnf-alpha refractori patient biosimilar
improv market access expect biolog penetr ulcer
coliti uc crohn cd increas
next year driven factor
uc induct complet end mainten data end
approv see cd timelin lag year
data oloranib ib pain data expect late
current model opportun note high
posit skew option readout
valuat increas tp introduc
cd revenu build forecast po etrasimod sale
rais uc po note arna current ev
strong balanc sheet pro forma cash see
attract lt target recommend invest ahead
regulatori risk commercial/competit headwind
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
arena biopharmaceut compani focus develop
novel small molecul drug optim receptor pharmacolog
diseas unmet need compani product candid
includ ralinepag pah etrasimod ulcer coliti
price apr rate outperform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
etrasimod success uc cd po
assign po etrasimod uc zero credit
indic ralinepag
grow convict
view arena among promis long-term idea coverag univers
attract valuat enterpris valu rock-solid balanc sheet
pro-forma cash wholly-own de-risk multibillion dollar potenti asset
etrasimod program etrasimod expect complet uc induct
studi end mainten data end support approv
think etrasimod data worth wait recommend investor build posit
next year well ahead major catalyst
uc/cd market larg current global biologic/novel agent sale estim
result highli competit outlin companion see note
someth get ger autoimmune/inflammatori market continu
grow histor preced demonstr similar grow therapeut indic
tend keep expand new mechan come market failur control
moderate-to-sever patient singl modal hallmark autoimmun
diseas model lt failur rate tnf-alpha antagonist owe failur
respond immunogen diseas heterogen factor expert check
confirm continu interest novel moa asset high unmet need express
expert convers oral treatment target uc/cd patient fail
respond mainstay tnf-alpha antagonist therapi estim current biolog novel
agent penetr uc/cd present anticip combin
penetr recent biolog entrant approv new oral agent biosimilar
tnf-alpha launch lead expans biologic/novel agent penetr
among moderate-to-sever uc/cd patient us
expect etrasimod achiev ww sale across uc cd assum
approv includ note introduc crohn diseas
revenu build patient moderate-to-sever crohn diseas
us model address pool etrasimod mainli
patient refractori front-lin biolog therapi primarili tnf-alpha antagonist
model ww sale crohn diseas reflect penetr
target market total biologic/novel agent market share
etrasimod may prove best-in-class oral agent uc cd
ulcer coliti trial treatment etrasimod daili led
statist signific improv clinic remiss rate vs placebo vs
week furthermor drug gener safe well-toler
view result favor compar etrasimod closest comp celgen
modul ozanimod support potenti best-in-class profil within uc space
specif advantag relat ozanimod includ
ozanimod delta percentag patient achiev clinic
remiss addit ozanimod delta clinic remiss rate exceed
even week long-term follow-up data present earlier
arena demonstr patient receiv mg dose experienc absolut
clinic remiss rate highest rate patient expos
mg throughout cours total treatment period addit
receptor etrasimod also target receptor may
direct benefici effect epitheli endotheli barrier function
differenti safeti profil ozanimod cv-relat sae lft-
relat sae uc induct trial etrasimod caus sae
mg cohort though fewer exposur etrasimod
note modul concern histor driven bradycardia av block
liver toxic associ first approv drug class
novarti mayzent siponimoid recent approv ms unlik gilenya
broadli requir first-dos cardiac monitor fda requir first-
dose observ among patient certain pre-exist cardiac condit
expect lower rate cardio base uc experi
need titrat expect etrasimod profil mitig regulatori
faster onset studi healthi volunt etrasimod abl reduc
peripher total lymphocyt count day mg compar
ozanimod lymphocyt reduct day mg may
attribut etrasimod direct activ rel ozanimod confer
efficaci primarili activ one activ metabolit lack
titrat may also contribut rapid efficaci observ rel
faster off-set studi etrasimod also demonstr complet recoveri
lymphocyt count day discontinu wherea ozanimod show
recoveri within baselin day discrep could potenti
attribut ozanimod activ metabolit half-lif
notabl differ could clinic meaning event patient develop
infect
etrasimod data crohn diseas yet believ may eventu also
develop best-in-class profil indic base aforement mechanist
qualiti believ ozanimod posit cd data open-label trial de-risk
etrasimod prospect figur show modul like effect
major inflammatori bowel diseas ozanimod cdai clinic remiss rate
phase competit latest approv therapi cd stelara
blocker though differ popul studi design open label uncontrol weaken
comparison
figur celgen stepston support class efficaci cd
ozanimod mg open-label trial crohn diseas
mean diseas durat year prior exposur biolog therapi
reduct baselin
reduct baselin
common sae two patient cd flare fistul diseas
intestin obstruct abdomin abscess
pictur may best oral agent win- jaki vs modul
next decad believ treatment ibd like increasingli includ novel
oral agent expect jak inhibitor modul emerg
promin player xeljanz non-select jak inhibitor current fda-
approv oral agent ibd indic moderate-to-sever uc mount sae
profil increas risk lung blood clot death observ rheumatoid arthriti post-
market studi gener seriou infect increas cv-risk concern
associ product like continu limit uptak
select jak inhibitor popul late-stag pipelin figur expect
compar better efficaci xeljanz improv safeti
toler profil howev believ modul specif etrasimod
like emerg oral agent choic time may abl differenti
safeti figur evid meaning efficaci see figur uc efficaci data
charl martineau pm univers toronto figur function role jak
gm-csf
epo tpo g-csf gh leptin
lif osm
ifn ifn
cell prolifer surviv
respons helminth
cell prolifer surviv
lymphocyt growth differenti
synoviocyt osteoclast function
figur modul jaki late-stag develop ibd
ww net sale
trial conduct mix subject nave receiv prior biolog therapi result reach statist signific
repres data week
remicad first approv drug uc
uc arena confirm plan fda expect initi
pivot studi base treat-through studi design could
report induct data end earli along mainten data
late earli set nda file late
cd near agreement fda initi adapt design
trial portion act pivot studi compani
hope abl file nda soon expect readout back-half
earli given compet enrol patient ibd clinic
trial employ undisclos proprietari methodolog expedit
ad trial expect commenc initi data could present
soon end earli
see arena potenti acquisit target long-term consid multi-billion dollar
potenti etrasimod option across indic late-stag statu
ulcer coliti inflammatori diseas local colon afflict
individu us per cdc physician treat diseas base
sever patient present patient consid moder
sever moder sever patient treat variou immunomodul
methotrex azathioprin relaps physician current hand
biolog novel agent armamentarium figur
figur novel agent moder sever uc
novel agent treatment ulcer coliti
mg/kg induct
week everi week
mainten hr
mg day mg
day mg day
mg everi week
mainten
mg induct week
mg week
mg everi week
mg induct
week everi week
mg twice daili
week mg twice
daili depend
expect etrasimod primari util uc patient popul
respond tnf-alpha antagonist either initi time collect exist
novel agent global net sale expect market grow
follow introduct oral agent pfizer xeljanz approv
blemish sae potenti signal suggest higher mortal use
higher dose etrasimod aid earli data suggest potenti
differenti efficaci safeti profil rel oral agent high patient churn
variou novel therapi assist rapid adopt key assumpt
follow
gross price year base xeljanz wac price
market entri assum treat-through clinic design oppos
estim proport patient continu receiv tnf-alpha
antagonist set progress decreas y-o-i
market share among tnf-alpha refractori patient estim
oral agent captur tnf-alpha antagonist non-respond market
etrasimod reach oral agent market
po base clear efficaci win robust ole data
us
discount us
us patient ulcer coliti
uc patient
moder sever patient
uc patient
recipi tnf-alpha
oral share market
yr
gross net discount
ex-u patient ulcer coliti
uc patient
moder sever patient
uc patient
recipi biologic/novel agent
accord cdc patient suffer cd us patient
develop worsen inflamm strictures/fistula higher probabl relaps
usual place biolog figur control diseas drive remiss
figur novel biolog moder sever cd
novel biolog treatment crohn diseas
mg/kg induct
week everi
week mainten
mg day mg
day mg day
mg everi
week mainten
mg induct
mg everi
week mainten
mg induct
week everi week
infus dose
mg sq everi week
expect cd market continu expand oral therapi ozanimod
approv approv oral therapi moderate-sever cd novel biolog
gener expert indic high unmet need still remain
high failur rate tnf-alpha inhibitor cd evidenc real-world studi follow
biolog user humira remicad cimzia evalu
sub-optimal biolog therapi data show particip experienc
indic sub-optimal biolog therapi within month within month
differ indic sub-optimal biolog therapi drug discontinu
frequent indic rang month
gross price year base xeljanz wac price
market entri expect file nda
conserv estim proport patient continu receiv
tnf-alpha antagonist set progress decreas y-o-i
market share estim oral agent captur tnf-
alpha antagonist non-respond market etrasimod reach oral
po present data etrasimod cd believ
ozanimod data open-label trial de-risk opportun extent
us patient crohn diseas
cd patient
moder sever patient
moder sever cd patient
recipi tnf-alpha
oral share market
share yr
gross net discount
ex-u patient crohn diseas
cd patient
moder sever patient
cd patient
recipi novel agent
us
discount us
atop dermat plan initi random double-blind pbo-control
studi later year expect data around end studi design
similar convent ad trial term durat size rational studi
etrasimod ad stem encourag anecdot dermatolog find
healthi volunt uc studi biolog connect dermatolog
diseas topic administr agonist previous shown efficaci ad
patient owe inhibit dendrit cell migrat regul langerhan cell
migrat aoki et al signal immun cell
inflamm role potenti rational includ
ad current under-penetrated moderate-sever market potenti
peak market opportun sanofi/regeneron dupix current
fda-approv drug segment larg number addit novel
agent test current
etrasimod could lead modul develop market meanwhil
jaki encompass major oral agent pipelin develop figur
expect ad market evolv one resembl psoriasi see
slide show detail current option inject provid solid
efficaci unmet need remain novel compound differenti
rel dupix high-dos cohort believ safeti profil may limit
commerci potenti time incid malign seriou infect
occur across differ indic select non-select
jaki
opportun etrasimod success demonstr efficaci competit
agent space similar safeti profil shown thu far
uc
figur late-stag oral compound ad
expect ad market evolv one resembl see note someth
get bigger autoimmune/inflammatori market continu grow
current option inject provid solid efficaci unmet need remain novel
compound differenti moa jak inhibitor efficaci data thu far suggest
competit profil rel dupix high-dos cohort believ safeti
profil may limit commerci potenti time incid malign seriou
infect occur across differ indic select non-select
jaki recent regulatori concern emerg around heighten thromboembol risk
 dvt ad could repres anoth dollar opportun etrasimod
success demonstr efficaci competit agent space similar
safeti profil shown thu far uc
figur modul jaki data uc
week
week
week
week
seriou infect vs
octav
vs octav
sae relat
bradycardia av block
degre av block sinu
bradycardia day
without intervent
patient mg
cohort mg cohort
increas lft
patient mg
cell carcinoma skin
patient enrol studi
inadequ respons
loss respons
intoler corticosteroid
immunosuppress
one event herp zoster
mg cohort one
melanoma mg cohort
major cv
filgotinib current avail data uc
etrasimod data evalu week
mg bid also
studi d/ced
earli corpor base
hyperlipidemia viral
treatment effect
anti tnf-alpha nave
similar trial
octav
across studi includ
treat pt adjud
adjud cv event
case malign
figur modul jaki data cd
prior exposur biolog therapi
fail intoler one
tnf inhibitor
tx cohort
reduct baselin
reduct baselin
common sae two
patient cd flare fistul diseas
intestin obstruct abdomin abscess
reduct baselin
reduct baselin
ae lead d/c
incid herp zoster
malign mg bid cohort
incid cv event
reduct baselin
ae lead d/c vs
posit data one indic alway
translat
though drug therapi manag cd uc similar etiolog
pathophysiolog geograph distinct cd uc led
clinic failur figur even clinic success achiev
indic rational discrep complet understood
heterogen diseas particularli cd present vari wide
anatom locat cd uc confin colon cd develop anywher along
gi tract often cite clinician potenti root caus
exampl
efficaci cd
efficaci uc
region tissu pathophysiolog differ small larg bowel
dose higher dose bio-avail may requir stabil therapeut issu
bilsborough et al therapeut target inflammatori bowel diseas current futur
compani mention price
